AbbVie stock forecast 2025 factors in macroeconomic variables such as interest rate stabilization and healthcare policy shifts. Equity strategists see ABBV benefiting from defensive positioning in volatile markets due to consistent dividend payouts. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. AbbVie’s oncology and neuroscience drugs are also contributing to top-line growth. AbbVie’s oncology segment generated combined revenues of $3.3 billion in the first half of 2025, up 4.2% year over year as higher sales of Venclexta and contributions from new drugs, Elahere and Epkinly, more than offset declining Imbruvica sales due to competitive pressure. Sales of its neuroscience drugs increased 20.3% to almost $5 billion in the first half of 2025, driven by higher sales of Botox Therapeutic, depression drug Vraylar and newer migraine drugs Ubrelvy and Qulipta. Long-term AbbVie stock forecast 2025 models anticipate free cash flow exceeding $20 billion if management executes pipeline launches. Price target adjustments from major brokerages tend toward $190–$210 based on forward growth assumptions.